Type 2 diabetes mellitus
Conditions
Interventions
Administration of glimepiride for 16 wks
Administration of nateglinide for 16 wks
Sponsors
Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Type 2 diabetic patients treated with voglibose for 12 wks or more 2) HbA1c level: 6.5%<=HbA1c<8.0% 3) Patients with HbA1c fluctuation of 0.5% or less during the 3 months prior to the beginning of the study 4) Patients without severe heart, liver or kidney diseases 5) Age: 20 to 79 years old 6) Outpatients
Exclusion criteria
Exclusion criteria: 1) Patients without type 2 diabetes 2) Patients with alcohol abuse or excessive intake of alcoholic beverages 3) Patients with severe diabetic complications* *nephropathy>=stage 3A *retinopathy>=preproliferative stage in Davis classifications 4) Patients with liver dysfunction (AST and ALT>=80 IU/L) or renal dysfunction (serum creatinie>=1.5mg/dl) 5) Patients with an allergy to any drug 6) Pregnant women and women at child bearing age and not taking adequate contraceptions 7) Patients decided to be irrelevant by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in HbA1c levels Changes in postprandial plasma glucose concentrations | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in 1,5-AG levels Changes in glycoalbumin levels Changes in insulin concentrations | — |
Countries
Japan
Outcome results
None listed